EU approves Shering-Plough's Bridion

The European Union approved Shering-Plough's Bridion (sugammadex) in an injection form for the purposes of reversing neuromuscular blockade during general anesthesia more rapidly. This will be the first product approval since Schering-Plough joined forces with Organon BioSciences. Release

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.